We also used BRAF and mitogen-activated protein kinase (MEK) inhibitors as postoperative adjuvant therapy for stage III melanoma, as Kamposioras et al. recommended that MUP be treated commensurately with the stage of MKP [3]. The gene discussed is WNK2; the disease is melanoma.